Literature DB >> 31961239

Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients.

Jie Yu1, Xu Zhang1, Hong Liu1, Ruiming Zhang1, Xiaoling Yu1, Zhigang Cheng1, Zhiyu Han1, Fangyi Liu1, Guoliang Hao1, Meng-Juan Mu1, Ping Liang1.   

Abstract

Background Percutaneous microwave ablation (MWA) and laparoscopic partial nephrectomy (LPN) are two modalities indicated for early-stage renal cell carcinoma (RCC) with low extent of invasion. Purpose To compare the long-term results of percutaneous MWA and LPN in the treatment of cT1a RCC. Materials and Methods This retrospective study included 1955 patients with cT1a RCC treated with percutaneous MWA or LPN between April 2006 and November 2017. Propensity score matching was used. Oncologic outcomes were analyzed by using the Fine-and-Gray competing risk models. Results A total of 185 patients underwent percutaneous MWA (mean age, 63.2 years ± 15.2 [standard deviation]) and 1770 underwent LPN (mean age, 50.9 years ± 13.2). During the follow-up (median, 40.6 months), after propensity score matching, no difference was observed between local tumor progression (3.2% vs 0.5%, P = .10), cancer-specific survival (2.2% vs 3.8%, P = .24), and distant metastases (4.3% vs 4.3%, P = .76). Patients who underwent percutaneous MWA had worse overall survival (hazard ratio, 2.4; 95% confidence interval: 1.0, 5.7; P = .049 vs LPN) and disease-free survival (82.9% vs 91.4%, P = .003). Percutaneous MWA led to smaller drop in estimated glomerular filtration rate at discharge (6.2% vs 16.4%, P < .001), smaller estimated blood loss (4.5 mL ± 1.3 vs 54.2 mL ± 69.2), lower cost ($3150 ± 2970 vs $6045 ± 1860 U.S. dollars), shorter operative time (0.5 minute ± 0.1 vs 1.8 minutes ± 0.6), and shorter postoperative hospitalization time (5.1 days ± 2.6 vs 6.9 days ± 2.8) (all P < .001 vs LPN). There were fewer cases of fever in the percutaneous MWA group (16.2% vs 73.0%, P < .001). Conclusion There were no significant differences regarding oncologic outcomes and complications between percutaneous microwave ablation and laparoscopic partial nephrectomy for patients with cT1a renal cell carcinoma. Percutaneous microwave ablation led to smaller renal function change and lower blood loss. For patients who cannot be subjected to the risks of more invasive laparoscopic partial nephrectomy, percutaneous microwave ablation could be an alternative less invasive treatment option. © RSNA, 2020 Online supplemental material is available for this article.

Entities:  

Year:  2020        PMID: 31961239     DOI: 10.1148/radiol.2020190919

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

1.  Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.

Authors:  Lei Shi; Yan He; Chang Liu; Xiaoyuan Qian; Zhixian Wang
Journal:  Cancer Med       Date:  2020-09-05       Impact factor: 4.452

2.  Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis.

Authors:  Brigit M Aarts; Fernando M Gomez; Marta Lopez-Yurda; Rob F M Bevers; Joris Herndriks; Regina G H Beets-Tan; Axel Bex; Elisabeth G Klompenhouwer; Rutger W van der Meer
Journal:  Eur Radiol       Date:  2022-09-06       Impact factor: 7.034

3.  A Systematic Review and Meta-Analysis of Minimally Invasive Partial Nephrectomy Versus Focal Therapy for Small Renal Masses.

Authors:  Lin Dong; Wang You Liang; Lu Ya; Liu Yang; Wei Qiang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

4.  Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study.

Authors:  Zhixian Wang; Yisheng Yin; Jing Wang; Yunpeng Zhu; Xing Li; Xiaoyong Zeng
Journal:  Front Oncol       Date:  2021-07-30       Impact factor: 6.244

Review 5.  Modern Management of Localized Renal Cell Carcinoma- Is Ablation Part of the Equation?

Authors:  Zev Leopold; Rachel Passarelli; Mark Mikhail; Alexandra Tabakin; Kevin Chua; Ronald D Ennis; John Nosher; Eric A Singer
Journal:  J Kidney Cancer VHL       Date:  2022-08-15

Review 6.  Quality of Life and Psychological Distress among Patients with Small Renal Masses.

Authors:  Liliana Vartolomei; Andrei Cotruș; Camelia Stanciu; Cristian Delcea; Marco Tozzi; Elena Lievore; Felice Crocetto; Francesco Del Giudice; Giuseppe Lucarelli; Matteo Muto; Matteo Ferro
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

7.  MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine.

Authors:  Zhaonan Li; De-Chao Jiao; Chaoyan Wang; Wenguang Zhang; Jing Li; Xinwei Han
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

8.  Mixed epithelial and stromal tumor of the kidney extending to the proximal ureter in a 41-year-old female.

Authors:  Alanna M Cruz Bendezú; T Hunt Batter; Patrick Mufarrij
Journal:  Urol Case Rep       Date:  2021-05-28

9.  A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time?

Authors:  Jie Yu; Hui Wang; Zhi-Gang Cheng; Fang-Yi Liu; Qin-Ying Li; Guang-Zhi He; Yan-Chun Luo; Xiao-Ling Yu; Zhi-Yu Han; Ping Liang
Journal:  Eur Radiol       Date:  2021-06-30       Impact factor: 5.315

10.  Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center.

Authors:  Giovanni Mauri; Francesco Alessandro Mistretta; Guido Bonomo; Nicola Camisassi; Andrea Conti; Paolo Della Vigna; Matteo Ferro; Stefano Luzzago; Daniele Maiettini; Gennaro Musi; Nicolò Piacentini; Gianluca Maria Varano; Ottavio de Cobelli And Franco Orsi
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.